COMPETITION BETWEEN ZIDOVUDINE-SENSITIVE AND ZIDOVUDINE-RESISTANT STRAINS OF HIV

被引:116
作者
MCLEAN, AR
NOWAK, MA
机构
[1] Zoology Department, Oxford University, Oxford
关键词
ZIDOVUDINE; MATHEMATICAL MODEL; POPULATION DYNAMICS; DRUG RESISTANCE;
D O I
10.1097/00002030-199201000-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To investigate competitive interactions between zidovudine-sensitive and resistant strains of HIV within the context of host-parasite population dynamic interactions between CD4+ cells and HIV. Design: A mathematical model of the population dynamics of CD4+ cells, sensitive HIV and resistant HIV is developed. Methods: The model is analysed numerically and analytically and model predictions are compared with previously published data on population dynamics of HIV and CD4+ cells in patients receiving zidovudine. A threshold result describing the critical dose of zidovudine above which resistant HIV will out-compete sensitive HIV is derived, as are expressions describing the critical effective doses for the eradication of sensitive and resistant strains. Numerical simulations of the dynamics of the shift from the pre-treatment, equilibrium to the treatment equilibrium are presented and an analytic expression approximating the time taken until virus growth restarts is derived. Results: It is shown that competition between strains of virus is the important factor determining which type of virus will eventually start to grow during the course of zidovudine treatment, but host-parasite interactions are the important determinant of when viral resurgence occurs. Conclusions: Although resistant strains are observed after prolonged treatment with zidovudine, this model suggests that it is the growing supply of uninfected CD4+ cells which causes the eventual upsurge in viral burden.
引用
收藏
页码:71 / 79
页数:9
相关论文
共 19 条
  • [1] ANDERSON R M, 1991
  • [2] VACCINATION AGAINST RUBELLA AND MEASLES - QUANTITATIVE INVESTIGATIONS OF DIFFERENT POLICIES
    ANDERSON, RM
    MAY, RM
    [J]. JOURNAL OF HYGIENE, 1983, 90 (02): : 259 - 325
  • [3] ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY
    BOUCHER, CAB
    TERSMETTE, M
    LANGE, JMA
    KELLAM, P
    DEGOEDE, REY
    MULDER, JW
    DARBY, G
    GOUDSMIT, J
    LARDER, BA
    [J]. LANCET, 1990, 336 (8715) : 585 - 590
  • [4] DOURNON E, 1988, LANCET, V2, P1297
  • [5] THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISCHL, MA
    RICHMAN, DD
    HANSEN, N
    COLLIER, AC
    CAREY, JT
    PARA, MF
    HARDY, WD
    DOLIN, R
    POWDERLY, WG
    ALLAN, JD
    WONG, B
    MERIGAN, TC
    MCAULIFFE, VJ
    HYSLOP, NE
    RHAME, FS
    BALFOUR, HH
    SPECTOR, SA
    VOLBERDING, P
    PETTINELLI, C
    ANDERSON, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) : 727 - 737
  • [6] THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISCHL, MA
    RICHMAN, DD
    GRIECO, MH
    GOTTLIEB, MS
    VOLBERDING, PA
    LASKIN, OL
    LEEDOM, JM
    GROOPMAN, JE
    MILDVAN, D
    SCHOOLEY, RT
    JACKSON, GG
    DURACK, DT
    KING, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) : 185 - 191
  • [7] INVIVO PREVALENCE OF AZIDOTHYMIDINE (AZT) RESISTANCE MUTATIONS IN AN AIDS PATIENT BEFORE AND AFTER AZT THERAPY
    FITZGIBBON, JE
    HOWELL, RM
    SCHWARTZER, TA
    GOCKE, DJ
    DUBIN, DT
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (03) : 265 - 269
  • [8] HIV WITH REDUCED SENSITIVITY TO ZIDOVUDINE (AZT) ISOLATED DURING PROLONGED THERAPY
    LARDER, BA
    DARBY, G
    RICHMAN, DD
    [J]. SCIENCE, 1989, 243 (4899) : 1731 - 1734
  • [9] POPULATION-DYNAMICS OF HIV WITHIN AN INDIVIDUAL AFTER TREATMENT WITH ZIDOVUDINE
    MCLEAN, AR
    EMERY, VC
    WEBSTER, A
    GRIFFITHS, PD
    [J]. AIDS, 1991, 5 (05) : 485 - 489
  • [10] 3'-AZIDO-3'-DEOXYTHYMIDINE (BW A509U) - AN ANTIVIRAL AGENT THAT INHIBITS THE INFECTIVITY AND CYTOPATHIC EFFECT OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-III LYMPHADENOPATHY-ASSOCIATED VIRUS INVITRO
    MITSUYA, H
    WEINHOLD, KJ
    FURMAN, PA
    STCLAIR, MH
    LEHRMAN, SN
    GALLO, RC
    BOLOGNESI, D
    BARRY, DW
    BRODER, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (20) : 7096 - 7100